BurnSlim VSL ãšåºååæ
BurnSlim ã®ãããªã»ãŒã«ã¹ã¬ã¿ãŒã®åé æ°ç§ã®ã©ããã§ãç¹å®ã®ä¿®èŸçãªè³ãã眮ãããŠããŸããèŠèŽè ã¯ãã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ãæ¯æãŒã©ãã³ã®ç«æ¹äœã 1 ã€é£ã¹ãããšã§ 68 æ¥éã§ 60 ãã³ãäœéãæžããããšèšãããŠããŸãâŠ
Restricted Access
+2,000 VSLs & Ads Scaling Now
+50â100 Fresh Daily · 34+ Niches · Personalized S.P.Y. · $29.90/mo
ã¯ããã«
BurnSlim ã®ãããªã»ãŒã«ã¹ã¬ã¿ãŒã®åé æ°ç§ã®ã©ããã§ãç¹å®ã®ä¿®èŸçãªè³ãã眮ãããŠããŸããèŠèŽè ã¯ãã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ãæ¯æãŒã©ãã³ã®ç«æ¹äœã 1 ã€é£ã¹ãããšã§ 68 æ¥éã§ 60 ãã³ãäœéãæžããããšèšãããŠããŸããMounjaro ãæçšããããšã§ã¯ãªããå人ãã¬ãŒããŒãéãããšã§ããªããã»ãšãã©ã®èšåºå»ããã®èŠæš¡ã®äœéæžå°ã«å¿ èŠã§ãããšèª¬æãããããªçš®é¡ã®èŠåŸçã§å€è§çãªã©ã€ãã¹ã¿ã€ã«ä»å ¥ãéããŠã§ããªãããŒã©ãã³ã®ç«æ¹äœããã®äž»åŒµã®å ·äœæ§ãã1 ã€ã®ç«æ¹äœããšããå¥åŠãªæ£ç¢ºããååã®ä»ããæåäººãæ£ç¢ºãªæ¥æ°ã¯å¶ç¶ã§ã¯ãããŸãããããã¯èŠèŽè ã®æåŸ ãæå³çã«äžæããããã®ã§ã仿¥ã®ã»ãšãã©ã®äººããããªã³ã³ãã³ããæ¶è²»ããæ¹æ³ãæ¯é ããã¹ã¯ããŒã«-ã¹ãããåå°ãæ¢ããããã«èšèšãããŠããŸãããã®äž»åŒµãçå®ã§ãããã©ããã¯ãããã广çã§ãããã©ãããšãã質åãšã¯å¥ã®è³ªåã§ãããã®åæã¯äž¡æ¹ã«é¢å¿ããããŸãã
VSL ã¯é©ãã¹ãé·ãã§å®è¡ãããå°ãªããšã 4 ã€ã®ç°ãªããã©ãã£ãã¹ã¬ãããç¹ãåãããŠããŸããæå人ã®å€èº«ç©èªãå»åž«ã®èµ·æºç©èªãè£œè¬æ¥çã®é°è¬ããããŠè£œåã®å ¬éã§ããããããã¹ãŠã®äžå¿ã«ããã®ã¯ BurnSlim ãšåŒã°ããäœéæžå°ãµããªã¡ã³ãã§ãããGLP-1 å容äœäœåè¬å»è¬åãç¹ã« Mounjaro ãš Ozempic ãçŸåšåæ¥çã«æ¯é ããŠããåãçç©åŠçã¡ã«ããºã ã«åºã¥ããŠæ§ç¯ãããã«ãã»ã«è£œå€ãšããŠæç€ºãããŠããŸãããã®ãããã¯ã2018 幎ã®ã¹ã¿ã³ãã©ãŒãèšåºã±ãŒã¹ã¹ã¿ãã£ãAstellas Labs ãšåŒã°ããæ¥æ¬ã®è£œè¬ç ç©¶æãšã®ææºãããã³ 1,956 ãè¶ ãã ãã©ã³ãã£ã¢è©Šéšãã1 åã®æ³šå°ããã $2,000 ãããå»è¬åã®å€©ç¶ã§å®äŸ¡ãªä»£æ¿æ¡ãæ€èšŒããŠããããšã䞻匵ããŠããŸããããã¯éåžžã«é©ãã¹ã䞻匵ã®ãã§ãŒã³ã§ãããããã¯åããããå³å¯ãªèªã¿ã«å€ããŸãã
ãã®ç¹å®ã® VSL ãç ç©¶ãã䟡å€ãããçç±ã¯ããã®èª¬åŸã¢ãŒããã¯ãã£ã®æŽç·Žãã§ããã¬ã¿ãŒã¯äžçŽç·ã§è²©å£²ãããŸãããæš©åšãç©ã¿éããæªåœ¹ãæ§ç¯ããæ·±ãå ±æçãªææ çãªãã©ãã£ããé 眮ããåžå°æ§ãéããŠç·æ¥æ§ã補é ãããã®åŸã賌買è¡çºãããŒãžãé¢ããè¡çºãããå°ãªãã³ãããã¡ã³ããå¿ èŠã§ããããã«ãã¬ãŒãã³ã°ãããããã«å®å šã«ãªã¹ã¯ãé転ãããŸãããããã®ååãã¯ã³ããŒã©ã€ãã£ã³ã°ãšè¡åå¿çåŠã®æç®ã«ååãæã£ãŠããŸãããããŠããããæ£ç¢ºã«ååä»ããããšã¯ã以äžã®ã»ã¯ã·ã§ã³ã®ç®çã§ãã
ãã®èšäºã調æ»ããäžå¿çãªè³ªåã¯åçŽã§ããBurnSlim ã¯äœãããã®è²©ä¿è³æã¯ç§åŠã¬ãã«ã§å®éã«äœã䞻匵ããŠãããããããã®äž»åŒµã¯ã©ã®çšåºŠå ç¢ãããã㊠VSL ã¯ã©ã®ãããªèª¬åŸã¡ã«ããºã ãé 眮ããŠæççãªè²·ãæãè³Œå ¥ã«åããããããããªããçŸåšãéã䜿ãåã«ãã®è£œåã調æ»ããŠãããªããããªãã¯ãŸãã«æ£ããå Žæã«ããŸãã
BurnSlim ãšã¯äœã?
BurnSlim ã¯ã«ãã»ã«åœ¢ã§å£²ãããŠããçµå£é£äºè£å©é£åã§ã1 æ¥ã« 2 ã€ã®ã«ãã»ã«ãç©ºè ¹æã«æåããŸãããã®è£œåã¯ä»£è¬äœéæžå°ã«ããŽãªãŒã«äœçœ®ä»ããããŠããŸããsemaglutide (OzempicãWegovy) ããã³ tirzepatide (Mounjaro) ã®ãã㪠GLP-1 å容äœäœåè¬å»è¬åã®äž»æµã®çªç Žã«ç¶ããŠããµããªã¡ã³ãæ¥çã®æã忥çã«æŽ»åçãªã»ã°ã¡ã³ãã® 1 ã€ã«ãªã£ã空éãBurnSlim ã®è¿°ã¹ãããå·®å¥åã¯ããããèªç¶ã« GLP-1 (ã°ã«ã«ãŽã³æ§ãããã-1) ããã³ GIP (ã°ã«ã³ãŒã¹äŸåæ§ã€ã³ã¹ãªãããããã¯ããªãããã) ã®äœèªèº«ã®ç£çãåºæ¿ããããšã䞻匵ããŠãããšããããšã§ããæ³šå°åŠæ¹å»è¬åãåæçã«æš¡å£ãŸãã¯äº€æããåã 2 ã€ã®ã€ã³ã¯ã¬ãã³ãã«ã¢ã³ããã®è£œå㯠AmazonãGNCããŸãã¯è¬å±ãã§ãŒã³ã§ã¯ãªããç¬èªã® Web ãµã€ãã®ã¿ãéããŠè²©å£²ãããŠããããã®é åžã®éžæã¯ VSL ãã³ã¹ãåæžãšããŠãã¬ãŒã åããŠããŸãããããã¯ç¬¬äžè ã®äŸ¡æ Œæ¯èŒãšå€éšã¬ãã¥ãŒãå¶éããæ©èœãæãããŠããŸãã
è¿°ã¹ãããã¿ãŒã²ãããŠãŒã¶ãŒã¯ 35 æ³ä»¥äžã®å¥³æ§ã§ãç¹ã«åºç£åŸã®äœéå¢å ãæŽå¹ŽæåšèŸºæãŸãã¯æŽå¹Žæäžã®äœéå¢å ããŸãã¯åŸæ¥ã®é£äºçæ³ãšéåãããã³ã«ã®ç¹°ãè¿ããã倱æãçµéšãã人ã ã«éç¹ããããŸããVSL ã¯ãŸããæ³šå° GLP-1 å»è¬åã詊ããŠå¯äœçšãŸãã¯åæ¢åŸã®ãªããŠã³ãäœéå¢å ãçµéšãããŠãŒã¶ãŒã«å¯ŸåŠããŸããMounjaro ãŸã㯠Ozempic ã®é·æäœ¿çšã«é¢ããææžåããã課é¡ãèãããšãæé·ãšäžæºã®ãã人å£ã§ããBurnSlim ã¯åŸæ¥ã®æå³ã§ã®ãµããªã¡ã³ãã§ã¯ãªããã«ããªãŒå°äœã®ç¡çåæ§è¡šé¢ã§ã¯ãªããèèªèç©ã®æ ¹æ¬çãªãã«ã¢ã³åå ã«å¯ŸåŠããã代è¬ãªã»ãããã·ã¹ãã ãšããŠæç€ºãããŠããŸãã
ãã®è£œåã®ãã©ã³ãã£ã³ã°ãšãã©ãã£ãã¯ãVSL ã«ãããšãçªçµã®åžäŒè ã§ãã Jennifer Ashton å士ãšããã人ç©ãããã³èªç¶ãªååç©ãå°éãšããç¬ç«ããæ¥æ¬ã®è£œè¬äŒç€ŸãšããŠèª¬æããã Astellas Labs ã®éã®ããŒãããŒã·ãããéããŠæ§ç¯ãããŸããã宿ããã«ãã»ã«è£œåã¯ãç±³åœã® FDA ç»é²ãGMP èªèšŒæœèšã§è£œé ãããŠãããšäž»åŒµãããŠããŸãããããã®èŠå¶èšè¿°å (FDA ç»é²ãGMP èªèšŒã第äžè ãã¹ã) ã¯ãµããªã¡ã³ãæ¥çã®æšæºèšèªã§ãããåºæ¬çãªè£œé åºæºãžã®æºæ ã瀺ããŸããã補åã®å¥åº·äž»åŒµã«é¢ãã FDA æ¿èªãæ§æããŸããã
ããã察象ãšããåé¡
BurnSlim ã® VSL ã蚺æããè¥æºã®åé¡ã¯å®åšãããããåŒçšããç«åŠããŒã¿ã¯éžæçã«äœ¿çšãããŠããŸãããçã®å ¬è¡è¡çäžã®æžå¿µãåæ ããŠããŸããäžçä¿å¥æ©é¢ã¯ã2022 幎çŸåšãäžçäžã®çŽ 25 åäººã®æäººãéäœéã§ããã890 äžäººä»¥äžãè¥æºãæ±ããŠãããšæšå®ããŠããããã㯠1975 幎以æ¥ã® 3 åè¿ãå¢å ã衚ããŠããŸããç¹ã«ç±³åœã§ã¯ãçŸç 管çäºé²ã»ã³ã¿ãŒã¯ãç±³åœäººã®æäººã®çŽ 41.9% ãè¥æºã®èšåºåºæºãæºãããŠããããšãå ±åããŠããŸããVSL 㯠2022 幎 3 æã® Science Direct åºçç©ãåŒçšãã1970 幎代以æ¥ã®è¥æºçã® 5 åè¿ãå¢å ãææãã2030 幎ãŸã§ã«äžççã« 10 å人ãè¥æºã§ç掻ãããšãã WHO ã®äºæž¬ãåç §ããŠããŸãããããã®æ°åã¯æ¹åçã«æ£ç¢ºã§ãããVSL ã«ãããããèµ·ãã£ãŠããçç±ã®å æèª¬æã¯äž»æµã®ç«åŠãã倧ããéžè±ããŠããŸãã
VSL ã®ãã¬ãŒãã³ã°ã®åé¡ã¯ããããäºéã®åœ¹å²ãæãããããæ éã«æ€èšãã䟡å€ããããŸããããã¯è£œåãæ§ç¯ãããŠããç§åŠã説æããåæã«èŠèŽè ãå人çãªè²¬ä»»ããè§£æŸããŸããããã¯ææ çã«éåžžã«å¹æçã§ãã䞻匵ã¯ã1970 幎以éã«å°å ¥ãããæ·»å ç©ãšé²è æã§æºããããçŸä»£ã®è¶ å å·¥é£åããGLP-1 ããã³ GIP ãšãã 2 ã€ã®ã€ã³ã¯ã¬ãã³ãã«ã¢ã³ã®äœã®èªç¶ãªç£çãäœç³»çã«ãããã¯ããŠãããšããããšã§ãããããã¯å éšããç Žå£ããããã«ã¢ã³ã·ã¹ãã ã§ãããšãåžäŒè ã¯èšããŸããããããŠèª°ãããããå®çŸããã« ãããçµéšããŠããŸããããã®å«æã¯ãè¥æºã¯åŸæ¥ã®æå³ã§ã®è¡åçãŸãã¯ç°å¢çç¶æ ã§ã¯ãªããé£åæ¥çã«ãã£ãŠæ°žä¹ åãããçååŠçç Žå£ã§ãããšããããšã§ãããã㯠false enemy frame (åœã®æµæ )ã責任ãå€éšã®æªæã®ããåã«è»¢æããä¿®èŸçãªè£ 眮ã§ãããèŠ³å®¢ã«ææžãšæ£åœãªæãã®äž¡æ¹ãçã¿åºããŸãã
ã€ã³ã¯ã¬ãã³ãã«ã¢ã³ã®å®éã®ç§åŠã¯ãGLP-1 ãš GIP ã飿¬²èª¿ç¯ãã€ã³ã¹ãªã³åæ³ã代è¬çã«éèŠãªåœ¹å²ãæãããŠãããšããèããæ¯æããŠããŸããDiabetes Care ããã³ The New England Journal of Medicine ãå«ãéèªã«æ²èŒãããç ç©¶ã¯ãè¥æºã®äººã ã¯çŠããåäœãšæ¯èŒããŠé£åŸã®GLP-1å¿çãéåããŠããããšã確ç«ããŸããããã ããã®é¢ä¿ã®å ææ¹åæ§ã¯äŸç¶ãšããŠè°è«ãããŠãããäœãGLP-1ã·ã°ãã«ãè¥æºãåŒãèµ·ãããããŸãã¯ããããçãããã¯ç¢ºå®ã«ç¢ºç«ãããŠããŸãããVSL ã¯ããã確ç«ãããç§åŠãšããŠæ±ã£ãŠãããçŸåšã®èšŒæ ãäžåããè¥æºæµè¡å šäœãåäžã®ãã«ã¢ã³ã¡ã«ããºã ã«å±æ§åããéºäŒççŽ å ãç¡ç ã®è³ªã瀟äŒçµæžçã¹ãã¬ã¹ãé£åç°å¢ãèº«äœæŽ»åã¬ãã«ãå«ãå€å åçãªçŸå®ãç¡èŠããŠããŸãã
ãã ããVSL ãæ£ç¢ºã«æããŠããã®ã¯ãåé¡ã®ææ çãªãã¯ã¹ãã£ã§ããã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã®ãã©ãã£ããåŠåš åŸã®äœéå¢å ãããããé£äºçæ³ã®è©Šè¡ãšæŸæ£ãå ¬å ±ããã³å ±éã§ã®å±èŸ±ã®çµéšã泚å°å»è¬åãžã®å ¥é¢ãé§è»ããè»ã§ã®æ³£ãããšãã¯ã察象ãšããèŠèŽè ã®éåžžã«å€§ããªã»ã°ã¡ã³ãã®å®ç掻ã®çµéšã«æ£ç¢ºã«å¯Ÿå¿ããŠããŸããåé¡ã¯åãªã代è¬çãªãã®ã§ã¯ãããŸãããããã¯ç€ŸäŒçãå¿ççããããŠç²ããŠããŸãããããŠããã®çµéšãæ£ç¢ºã«ååãä»ããããšããå§ãŸã補åã¯ããã®åŸã«ç¶ããã®ã«é¢ä¿ãªããèŠèŽè ããç°åžžã«é«ãã¬ãã«ã®åæä¿¡é ŒãåŸãŸãã
ä»ã® VSL ããã®ãããã§ãããã®ããããã©ã®ããã«æ§æããŠããã®ãèå³ããããŸãã?次ã®ã»ã¯ã·ã§ã³ã§ã¯ãBurnSlim ã®äž»åŒµãããã¡ã«ããºã ãæ€èšŒããŸããç§åŠãæãç«ã€å ŽæãšäŒžã³ãå Žæãå«ããæåãªã¹ããããéãç®ã§èªãããšãã§ããããã«ããŸãã
BurnSlim ã®ä»çµã¿
VSL ãææ¡ããã¡ã«ããºã ã¯ãç¹å®ã®çç©åŠç䞻匵ã«åºã¥ããŠæ§ç¯ãããŠããŸãããŒã©ãã³ã«å«ãŸãã 2 ã€ã®ã¢ããé ž (ã°ãªã·ã³ãšã¢ã©ãã³) ã¯è žã®ç¥çµäŒéç©è³ªãšããŠæ©èœããGLP-1 ãš GIP ã®èªç¶ãªç£çãåºæ¿ããå容äœã掻æ§åããŸãããããã®ãã«ã¢ã³ãäžæãããšãç©èªã¯ç¶ããè³ã¯ç¶ç¶çãªæºè ¹æä¿¡å·ãåãåããäœã¯é£åãç·æ¥èèªãšããŠä¿åããã®ãããã代è¬ã¯ç¶ç¶çãªèèªççŒç¶æ ã«ã·ããããŸãããã®åŸããã©ãŒãã¥ã©ã¯ 3 ã€ã®ãµããŒãæå (ç·è¶æœåºç©ããã«ããªã³ããŠã³ã³ (é»ã³ã·ã§ãŠæœåºç©) ã远å ããŠããã«ã¢ã³ç£çãå¢å¹ ããæ¥éãªäœéæžå°äžã®ç®èã®ããã¿ãé²ããè žã®ççãæžãããŠãã«ã¢ã³åå®¹äœæŽ»æ§ããããã¯ããŸãããã®è£œåã¯ãèªå® ã§ã®æºåã§ã¯éæäžå¯èœãªãèšåºçã«èšŒæããããæ¿åºŠã§ãã® 4 æåãããã³ã«ã®è£œè¬ã°ã¬ãŒãã®ã«ãã»ã«åãšããŠæç€ºãããŠããŸãã
確ç«ãããç§åŠãšåŠ¥åœãªå€æ¿æ³ããããŠææ©çãŸãã¯è£ä»ãã®ãªã仮説ãåé¢ãã䟡å€ããããŸãã飿¬²èª¿ç¯ããã³ ã°ã«ã³ãŒã¹ä»£è¬ã«ããã GLP-1 ãš GIP ã®åœ¹å²ã¯ç¢ºå®ã«ç¢ºç«ãããŠããŸããTirzepatide (Mounjaro) ãš semaglutide (Ozempic) ã¯ãäœèªèº«ã®ãããããããã¯ããã«é«ãã¢ãã£ããã£ãšæéã§ãããã®ãã«ã¢ã³ã®å容äœã«çµåããããšã§æ©èœããŸãããã®ã¡ã«ããºã ã¯è°è«ã®äœå°ããããŸããã質åã¯ãé£äºã®ã¢ããé žãç¹ã«ã°ãªã·ã³ãšã¢ã©ãã³ããèšåºçã«ææãªäœéæžå°ãçæããçšåºŠã«ææã«å å æ§ GLP-1 ãš GIP åæ³ãåºæ¿ã§ãããã©ããã§ãããã¢ã¬ãã¥ãŒæžã¿æç®ã§ã®çãã¯ãã¿ã³ãã¯è³ªãšç¹å®ã®ã¢ããé žã¯é£åŸã®ã€ã³ã¯ã¬ãã³åæ³ãåºæ¿ãããšãã蚌æ ããããŸãããé£äºç ç©¶ã§èгå¯ããã广ãµã€ãºã¯æ§ããã§ãããè¬çåŠçã«éæããããã®ãããã¯ããã«äœããšããããšã§ããVSL ã®äž»åŒµã¯ãã°ãªã·ã³ã GLP-1 ã¬ãã«ãã182%ãäžããããšãã§ããã¢ã©ãã³ãã144%ãã ã GIP ãäžããããšãã§ãããšããããšã§ãããã¹ã¿ã³ãã©ãŒããšã€ã§ãŒã«ã«å±ããŠããŸããç§åŠã³ãã¥ããã£ãç»æçã§ãããšèªèããŠããåºãåŒçšãããŠããå ¬éç ç©¶ã«å¯Ÿå¿ããŠããªãåçãªçºèŠã衚ãã§ãããã
ç·è¶æœåºç©ãç¹ã«ãã®ã«ããã³ååç© EGCG ã¯ãAmerican Journal of Clinical Nutrition ã«æ²èŒãããç ç©¶ã«ãã£ãŠãµããŒãããããèèªé žåãšäœç±ç£çãžã®ææžåãããæ§ãããªå¹æãæã£ãŠããŸãããã«ããªã³ã¯è¡æ¶²ã°ã«ã³ãŒã¹èª¿ç¯ã®ããã«ç ç©¶ãããŠããã代è¬çç¶æ³ã§æ¬ç©ã®çŽæã瀺ããŠãããMetabolism ã® 2012 幎ã®ã¡ã¿åæã¯ç©ºè ¹æã°ã«ã³ãŒã¹ãšè質ãããã¡ã€ã«ã§ææãªå¹æãçºèŠããŸããããã«ããªã³ãã³ã©ãŒã²ã³ç£çãšç®èåŒŸåæ§ãã5 åãå¢å ããããšãã䞻匵ã¯ãObesity Research ã® 2019 幎ã®ç ç©¶ã«å±ããŠãããæ€èšŒããã®ãé£ããããã«ããªã³ã®ææžåãããæççç¹æ§ã®çŸåã§ããå¯èœæ§ããããŸãããŠã³ã³ãšé»ã³ã·ã§ãŠã®çµã¿åããã¯ãããè¯ããµããŒããããŠãã倩ç¶ã®æçççµã¿åããã® 1 ã€ã§ããé»ã³ã·ã§ãŠæœåºç©ã«ããã¯ã«ã¯ãã³ã®ãã€ãªã¢ãã€ã©ããªãã£åäžã¯æå€§ 2,000% ã§ããããã㯠Shoba ã (1998) ã«ãã£ãŠ Planta Medica ã«æ²èŒãããå®éã®çºèŠã§ãããVSL ã®æ°å°ãªãå ·äœçãªåŒçšã® 1 ã€ã§ãããå®éã®æ€èšŒå¯èœãªç ç©¶ã«å¯Ÿå¿ããŠããŸãã
æ£çŽãªèŠçŽãBurnSlim ã®åã ã®æåã®ããã€ãã¯ãé©åãªçšéã§ã®ä»£è¬ãæççããŸãã¯èèªé žå广ã®ããã®åæ³çãªç§åŠçæ¯æãæã£ãŠããŸããäžå¿çãªäž»åŒµããã®çµã¿åãããèªç¶ã« GLP-1 ãš GIP ç£çãå®å šã«å掻æ§åããããšã§ Mounjaro ãã亀æãããé£äºçæ³ãéåã倿Žããã« 15 æ¥éã§ 27+ ãã³ãã®èèªæå€±ãçæããŸããã¯ãå ¬éäžã®åçã®ç¬ç«ããããã¢ã¬ãã¥ãŒæžã¿ã®èšŒæ ã«ãã£ãŠãµããŒããããŠããŸãããã劥åœãªçç©åŠçã¡ã«ããºã ããšãé£äºçæ³ãéåã倿Žããã« 2 ã¶æåã§ 61 ãã³ããã®ã®ã£ããã¯éåžžã«å€§ãããVSL ã¯ããã«ã€ããŠæ£çŽã«èª¬æããŸããã
äž»èŠãªæåãšã³ã³ããŒãã³ã
BurnSlim ãã©ãŒãã¥ã©ã«ã¯ 4 ã€ã®äž»èŠæåãå«ãŸããŠããããããããå®å šãªãã«ã¢ã³ããã³ä»£è¬å¹æã«äžå¯æ¬ ã§ãããšããŠæç€ºãããŠããŸããVSL ã¯ãæ¯çãèšåºçã«æ£ç¢ºã§ããããããã®ååç©ã®äžè¬çãªåºé çã§ã¬ããªã±ãŒãã§ããªãããšãæç€ºããŠããŸãã
ãŒã©ãã³ (ã°ãªã·ã³ãšã¢ã©ãã³ã¢ããé ž): ãŒã©ãã³ã¯ã³ã©ãŒã²ã³ããåŸãããã¿ã³ãã¯è³ªã§ãã°ãªã·ã³ãšã¢ã©ãã³ã®ã¢ããé žãè±å¯ã§ããã°ãªã·ã³ã¯ç¥çµäŒéç©è³ªãã°ã«ã¿ããªã³ã®åé§äœãšããŠã®åœ¹å²ãå«ãè€æ°ã®ççåŠçæ©èœãæãããŸããäžéšã®åç©ç ç©¶ãšå°èŠæš¡ãªãã詊éšã¯ãã°ãªã·ã³ãL现èãã GLP-1 åæ³ãæ§ããã«åºæ¿ããå¯èœæ§ã瀺åããŠããŸããVSL ã¯ãã°ãªã·ã³ã GLP-1 ã 182% å¢å ãããã¢ã©ãã³ã GIP ã 144% å¢å ãããããšã䞻匵ããã¹ã¿ã³ãã©ãŒããšã€ã§ãŒã«ãåŒçšããŠããããããã®äž»åŒµã¯ã¢ã¯ã»ã¹å¯èœãªç§åŠæç®ã®ç¹å®ã®å ¬é詊éšã«è¿œè·¡äžå¯èœã§ãããŒã©ãã³èªäœã¯èæ§ãè¯ããäŸ¡æ Œãå®ããé£åããã³è£œè¬è£œé ã§ã®é·ãäœ¿çšæŽããããŸãã
æ¥æ¬ã®ç·è¶æœåºç© (EGCG): ãšãã¬ãã«ããã³ã¬ã¬ãŒã (EGCGã¯ç·è¶ã®äž»èŠãªãã€ãªã¢ã¯ãã£ãã«ããã³ã§ããã代è¬å¹æã«ã€ããŠæãåºãç ç©¶ãããŠãã倩ç¶ååç©ã® 1 ã€ã§ããInternational Journal of Obesity (Hursel ãã2009) ã«æ²èŒãããã¡ã¿åæã¯ãç·è¶ã«ããã³ãšã«ãã§ã€ã³ã®çµã¿åãããäœéãšè °åšå²ã®ãããã§ã¯ãããçµ±èšçã«ææãªåæžããããããããšãçºèŠããŸãããVSL ã®å¥³æ§ãã2 åã®ãè ¹èèªãã倱ããšãããã®æœåºç©ã®äž»åŒµã¯ãææžåããã广ãµã€ãºãäžåã£ãŠããããã§ãããåºç€ãšãªãã¡ã«ããºã (軜床ã®äœç±ç£çãšèèªé žå) ã¯ç§åŠçæ ¹æ ããããŸãã
ãã«ããªã³: Berberis vulgaris ãå«ãããã€ãã®æ€ç©ã«å«ãŸããã¢ã«ã«ãã€ãã§ãããã«ããªã³ã¯ãäž»ã«è¡æ¶²ã°ã«ã³ãŒã¹ãè質ãããã¡ã€ã«ãè žå ãã€ã¯ããã€ãªã ã®çµæã«å¯Ÿãã广ã«ã€ããŠç ç©¶ãããŠããŸããMetabolism (Dong ãã2012) ã®ã¡ã¿åæã¯ãã¿ã€ã 2 ç³å°¿ç ã®æ£è ã«ãããç©ºè ¹æè¡äžã°ã«ã³ãŒã¹ãš LDL ã³ã¬ã¹ãããŒã«ã®ææãªäœäžãçºèŠããŸãããããæè¿ã®ç ç©¶ã¯ãã¡ããã«ãã³ãšã¡ã«ããºã çã«éãªã AMPK 掻æ§åã«å¯Ÿãããã«ããªã³ã®å¹æãæ¢çŽ¢ããŸãããVSL ã®ç®èåŒŸåæ§ã®äž»åŒµ (ã³ã©ãŒã²ã³å¢å 5 å) ã¯ææ©çã§ãããæšæºæç®ã§è¿œè·¡å¯èœãªç ç©¶ã«ãã£ãŠãµããŒããããŠããŸããã
ãŠã³ã³ (ã¯ã«ã¯ãã³) ãšé»ã³ã·ã§ãŠ (é»ã³ã·ã§ãŠæœåºç©) ã®çµã¿åãã: ã¯ã«ã¯ãã³ãšé»ã³ã·ã§ãŠã®çµã¿åããã¯ã倩ç¶ã®æççç ç©¶ã§æãåæ³çã«ãµããŒããããŠãããã¢ãªã³ã°ã® 1 ã€ã§ããShoba ã (1998)ãPlanta Medica ã«æ²èŒãããç ç©¶ã¯ã20 mg ã®é»ã³ã·ã§ãŠãã¯ã«ã¯ãã³ãšåææäžãããšããã被éšè ã«ãããŠã¯ã«ã¯ãã³ã®ãã€ãªã¢ãã€ã©ããªãã£ãçŽ 2,000% å¢å ãããããšãå®èšŒããŸããããã㯠VSL ã®æ€èšŒå¯èœã§æ£ç¢ºãªåŒçšã® 1 ã€ã§ããã¯ã«ã¯ãã³èªäœã¯å€æ°ã®ç ç©¶ã§æçç广ãå®èšŒããŸãããè žã®ççã®äœäžã VSL ã説æããçšåºŠã®ã€ã³ã¯ã¬ãã³ãã«ã¢ã³ã®å埩ãšäœéæžå°ã«å€æããããã©ããã¯ãå¯Ÿç §å®éšã§ã¯å®èšŒãããŠããŸããã
ãã㯠ãšåºåã¢ã³ã°ã«
VSL ã®ãªãŒããã³ã°ããã¯ãæ¯æ¥ãã®ããããªãŒã©ãã³ããªãã¯ã®ç«æ¹äœã 1 ã€é£ã¹ãã ãã§ãã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã¯ãã£ã 68 æ¥éã§ 60 ãã³ãæžéããã®ã¯ãªãã§ãã?ãã¯ãEugene Schwartz ã Stage 4 market sophistication (ã¹ããŒãž 4 åžå ŽçæŽç·Ž) ã¢ãããŒãã«åé¡ããã§ãããæç§æžçãªäŸã§ããåžå Žãäœéæžå°ã®äž»åŒµã§é£œåããŠãããè²·ãæã¯çŽæ¥çãªããããžã®èæ§ãéçºããå ·äœçãªã奜å¥å¿ãåŒãåºã圢åŒã§æç€ºãããæ¬åœã«ç®æ°ããã¡ã«ããºã ãéããŠã®ã¿å°éã§ããåžå Žã質å圢åŒã¯æå³çãªãã®ã§ãã声æã¯æçè«ãåŒãèµ·ãããŸããã質åã¯èŠèŽè ã«äž»åŒµãæ¡ä»¶ä»ãã§ä¿æããè³ãçããæ€çŽ¢ããç¶æ ã«æåŸ ããŸããããã¯æã open loop (ãªãŒãã³ã«ãŒã) ãšåŒã°ããå¿çåŠçç¶æ ã§ã (Cialdiniã2006)ãã1 ã€ã®ç«æ¹äœããšã68 æ¥ãã®ç¹ç°æ§ã¯è¿œå ã®ä»äºãå®è¡ããŸããæŒ ç¶ãšãã䞻匵ã¯ããŒã±ãã£ã³ã°ã®ããã«èŠããŸãããæ£ç¢ºãªäž»åŒµã¯ããŒã¿ã®ããã«èŠããèŠèŽè ã® System 1 åŠçã¯ãæ€èšŒãå¿ èŠãšããã«åŸè ãããä¿¡é Œã§ãããšæ±ããŸãã
ããã¯ã¯ãŸããã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã®å ¬éææžåãããäœéã®èŠåŽã远ã£ãŠãã誰ããçµéšããã§ããã identity threat (ã¢ã€ãã³ãã£ãã£è åš) ãšãèŠåºãã瀺åããåªåã®ãªãå€èº«ãç±æãã誰ããçµéšããã§ããã status frame (ã¹ããŒã¿ã¹ãã¬ãŒã ) ãå®è¡ããŸãããå¥åŠãªãŒã©ãã³ããªãã¯ããšãããã¬ãŒãºã¯ curiosity gap (奜å¥å¿ã®ã£ãã) ãå°å ¥ããŸããèŠèŽè ã¯ããªãã¯ãäœã§ãããããããŸãããç¥ããªãããšã®äžå¿«æã¯ãããèªäœãç¶ç¶ããŠèŠèŽããåŒãåºãã§ããããã 3 ã€ã®ã¡ã«ããºã (ãªãŒãã³ã«ãŒããã¢ã€ãã³ãã£ãã£è åšã奜å¥å¿ã®ã£ãã) ãåæã« VSL ã®æåã®æã§çºç«ããŠããããšã¯ãé倧ãªãã¹ããéããŠæŽç·ŽãããæŽç·Žããããšã³ããªãŒãã€ã³ãã衚ããŠããŸãã
VSL ã§èгå¯ãããã»ã«ã³ããªããã¯:
- ããã㯠Mounjaro ãæ¯æ¥æåããŠããããã§ãããå¯äœçšã¯ãããŸããããæ¢ç¥ã®å»è¬åãã©ã³ãããã®åçšãããä¿¡é Œæ§
- ãããªãã®ããã«æ©èœããªãå Žåãå»åŠåŠäœãç Žãè£ããŸãããä¿¡é Œæ§ä¿¡å·ãšããŠæ©èœããæ¥µç«¯ãªæš©åšã³ãããã¡ã³ã
- ãè£œè¬æ¥çã¯ãã®åžå ŽãæäœããŠããããé°è¬ãã㯠(確ç«ãžã®äžä¿¡ã掻æ§åããã
- ãJAMA ã®ç ç©¶ã¯ãGLP-1 ãš GIP ãæŽ»æ§åãã人ã ã 74 åå€ãäœéã倱ãããšã蚌æããŸããããæš©åšåŒçšçµ±èšã·ã§ãã¯ããã¯
- ã説æãªãè§£éãããŸããããæå¶ãã©ãã£ãã匷åããæ®æããã¯
Meta ãŸã㯠YouTube ãã¹ãçšã®åºåèŠåºãã®ããªãšãŒã·ã§ã³:
- ã圌女㯠60 ãã³ãæžããããã㯠Ozempic ã§ã¯ãªãã圌女ã®å»è ãæããã $49 ã®æã®ç¿æ £ã§ããã
- ããŒã©ãã³ããªã㯠Big Pharma 㯠TV ããå€ãããã« $179M ãè²»ãããŸããã
- ãããã¥ã©ã« Mounjaro?ãã®ãã® 4 æåã«ãã»ã«ã¯ GLP-1 ãã«ã¢ã³ã掻æ§åããããšã䞻匵ããŠããŸãã
- ãå»åž«ãããã 10 å¹Žã§æãè¡æçãªäœéæžå°çºèŠãšåŒã¶çç±ã
- ãæ¯æ 1 ã«ãã»ã«ããžã ãªããé£äºçæ³ãªãã2 é±éç®ã«äœãèµ·ãã£ãããèªããã
å¿ççããªã¬ãŒãšèª¬åŸæŠè¡
ãã® VSL ã®èª¬åŸã¢ãŒããã¯ãã£ã¯ç°åžžã«æŽç·ŽãããŠããŸãããªããªããããã¯å¹³è¡ã«é 眮ãããã®ã§ã¯ãªããã¡ã«ããºã ãé æ¬¡ã¹ã¿ãã¯ããããã§ããã»ãšãã©ã®äžéå±€ã®äœéæžå° VSL ã¯ç€ŸäŒç蚌æ ãå眮ãããã®åŸãªãã¡ãŒãè¡ããŸãããã®ã¬ã¿ãŒã¯å®å šãªææ çãªãã©ãã£ãã®åŒ§ãå®è¡ããçã¿ã確ç«ããéé£ãæ€èšŒããæªåœ¹ãäœæããæäžäž»ãå°å ¥ããã¡ã«ããºã ãæäŸããæš©åšãæ§ç¯ããåžå°æ§ã補é ããäŸ¡æ Œãèšåãããåã«ãªã¹ã¯ãé転ãããŸããçµæãšããŠããªãã¡ãŒãçå°ãããŸã§ã«ãèŠèŽè ã¯ææãªæéãææ çã«äžæããç¶æ ã«ãããLerner ãš Keltner (2001) ã«ããææ ãšæææ±ºå®ã«é¢ããç ç©¶ããªã³ã¯ ããŠããæ¡ä»¶ããã®ç¶æ ã¯ãããäœãææ ®åå¥ãªåŠçãšæå€±ãã¬ãŒãã³ã°ãžã®é«ãæåæ§ã«ã€ãªãããŸãã
ã¬ã¿ãŒã¯ãŸããè²·ãæã¯æåã«ã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã®çã¿ (å ¬ã®å±èŸ±ã倱æããé£äºçæ³ãé§è»ããè»ã§ã®æ³£ã) ãšåäžèŠããããæåŸ ããã stacked identity transfer (ç©ã¿éããããã¢ã€ãã³ãã£ãã£è»¢é) ãšåŒã°ãããããããªããã®ãå®èšŒããŠããŸãããã®åŸã圌女ã®å€èº« (èªä¿¡ãèªãèšèãå æ²¢ã®ããé»ããã¬ã¹) ãšåäžèŠããæçµçã«æ¢ã«æåããã114,000 人ã®å¥³æ§ãã®ã³ãã¥ããã£ãšåäžèŠããŸãã賌買決å®ãå°çãããŸã§ã«ãèŠèŽè ã¯å¿ççã«ååŸã®åŒ§å šäœãèªåãã¡ã®ã¹ããŒãªãŒãšããŠãªããŒãµã«ããŸãããããã¯ãè¡åçµæžåŠè Thaler ãš Sunstein ãè¡åã®åŒ·åãªãã©ã€ããŒã§ãããšç¹å®ãã mental simulation (粟ç¥ã·ãã¥ã¬ãŒã·ã§ã³) ã®åœ¢åŒã§ãã
æåäººã®æš©åšãéãã瀟äŒç蚌æ (Cialdiniã1984): ã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã®ææžåãããå ¬ã®äœéæžå°ãã¡ãã£ã¢ã§åºãå ±éãããå®éã®ã€ãã³ããã¯å®å šã« BurnSlim ã«å±æ§åãããæ¢åã®æåçãªãã©ãã£ãã補åã®æšå¥šã«å€æããŠããŸããã»ã«ã³ããªæå人 (Rebel WilsonãKaty PerryãOprahãKathy Bates) ã¯ãããã¥ã¡ã³ããŒã·ã§ã³ ã®ãªã蚌èšãšããŠè¿œå ãããæé»ã®æ€èšŒã®ã«ã¹ã±ãŒããäœæããŠããŸãã
æå€±åé¿ãã¬ãŒãã³ã° (Kahneman ãš TverskyãProspect Theoryã1979): VSL ã®æåŸã®ã2 ã€ã®ãªãã·ã§ã³ãã¯ããŒãºã¯æå€±åé¿ã®çŽæ¥çãªé©çšã§ãããªãã·ã§ã³ 1 (äœãããªã) ã¯ç Žå±çãªçšèªã§æãããŠããŸããå¿èç ãã¢ã«ããã€ããŒãçæ¶¯æ¯åº $239,000ã瀟äŒçå€ç«ããªãã·ã§ã³ 2 (è³Œå ¥) ã¯æ¯èŒã§ã³ã¹ããªããšããŠãã¬ãŒãã³ã°ãããŠããŸããé察称æ§ã¯æå³çã§ãããæå€±ãçæ¶¯æ¯åºãšã»ãŒåçã®ã²ã€ã³ããããããããã倧ããããŒãã³ã°ããŠããããšãçºèŠããååã«ææžåãããçºèŠãå©çšããŸãã
åœã®æµ / é°è¬ãã¬ãŒã (Godin ã®éšæããŒã±ãã£ã³ã°): ãBig Pharmaããå®ã倩ç¶ã®æ²»çæ³ãæãããããã« Jennifer Ashton å士ãè§£éããçµ±äžãããæªæã®ããåãšããŠæ§ç¯ããããšã§ãVSL ã¯å åŽã®ã°ã«ãŒãã¡ã³ã㌠(ä»ã¯ãçå®ãç¥ã£ãŠãããèŠèŽè ) ãšå€åŽã®ã°ã«ãŒã (圌ãã®èŠãã¿ããå©çãåŸãŠããç£æ¥) ã®éšæãäœæããŸããBurnSlim ã®è³Œå ¥ã¯ãåãªãæ¶è²»è ååŒã§ã¯ãªããéšæã®ææºãšåéã®è¡çºã«ãªããŸãã
æš©åšã¹ã¿ããã³ã° (Cialdini ã®æš©åšåå): ã³ãã³ãã¢å€§åŠãABC NewsãGood Morning AmericaãããŒããŒããã¹ã¿ã³ãã©ãŒããJAMAãWHOãCMS ããã¹ãŠã¬ã¿ãŒã®æåã® 3 åã® 1 以å ã«åŒã³åºãããŸãã环ç©å¹æã¯ãåŸç¶ã®äž»åŒµãé¢é£ä»ãã«ãã£ãŠæ€èšŒãããããã«æãããããªç°å¢ä¿¡é Œæ§ãã£ãŒã«ãã§ãããç¹å®ã®åŒçšãããç ç©¶ã¯ç¬ç«ããŠæ€èšŒããããšãã§ããŸããã
åžå°æ§ãšã³ãžãã¢ãªã³ã° (Cialdini ã®åžå°æ§åå): ã74 ããã«ã®ã¿æ®ã£ãŠãããã6 ã¶æããšã®å°ãããçç£ãæåã® 10 ããã³æåã® 25 人ã®è²·ãæã®ããã®æ®µéçãªããŒãã¹ã¯ãå§çž®ç·æ¥æ§æ§é ãäœæããŸããç¹å®ã®æ°å 74 (äžžæ°åã§ã¯ãªã) ã¯çæ£æ§ã瀺ããŸããæ£ç¢ºãªåšåº«æ°ã¯äžžæ°åãããçŸå®çã«æããŸãã
ãªã¹ã¯é転ãšã³ãããã¡ã³ãè»å (Thaler ã® endowment effect): 60 æ¥éã®ãã¹ãŠã®ããã«ãä¿æããã¬ã©ã³ãã£ã¯ããã¯ãããã å€åããå¿ èŠãšãããšããŠãã¬ãŒãã³ã°ãããŠãããååŒãã³ãããã¡ã³ãã§ã¯ãªã詊éšãšããŠãªãã¬ãŒãã³ã°ããããšã§è³Œè²·ãžã®å¿ççããªã¢ãåçã«äœäžãããŠããŸããThe endowment effect (å ç¥å¹æ) ã¯ãè²·ãæã補åãåãåããšãåãåãåãããé«ã䟡å€ãé©åã«è©äŸ¡ããè¿éã®å¯èœæ§ãæžãããšäºæž¬ããŠããŸãã
Epiphany bridge narrative (Russell Brunson ã®ã¹ããŒãªãŒããªã³ã°ãã¬ãŒã ã¯ãŒã¯): VSL ã¯èŠèŽè ã Jennifer Ashton å士ã®èªèº«ã®çºèŠã¢ãŒã¯ (2018 幎ã®ã¹ã¿ã³ãã©ãŒãã±ãŒã¹ã¹ã¿ãã£ãæ·±å€ã®èªããè¡æçãªãã«ã¢ã³ããŒã¿ããŠã€ã«ã¹ã® Facebook ãã¹ããæ¥æ¬ã®ç ç©¶æããŒãããŒã·ãã) ãéããŠã¹ããããã€ã¹ãããã§æ¡å ããŸããããã¯ãèŠèŽè ãç§åŠè ã®æ¬ç©ã®ãahaãç¬éãåäœéšããŠãããšæããããã«èšèšããã ã·ãŒã±ã³ã¹ã§ãããã®ãã¯ããã¯ã¯ãèªãæã®ä¿¡å¿µãèŠèŽè èªèº«ã®æŽå¯ã§ãããã®ããã«èŠèŽè ã«è»¢éããŸãã
å¥åº·ãšäœéæžå°ã¹ããŒã¹ã® 50+ ã® VSL å šäœã§ãããã®å¿ççæŠè¡ãã©ã®ããã«æ¯èŒãããããèŠããã§ãã?ããã¯ãŸãã« Intel Services ãèŠããããã«æ§ç¯ããããã®ã§ãã
ç§åŠçããã³æš©åšã·ã°ãã«
ãã® VSL ã®æš©åšã¢ãŒããã¯ãã£ã¯ãåæ³çãªèªå®ãèªå€§è«æ±ãæã€ã¯ã¬ãŒã ããã³å°ãªããšã 1 ã€ã®æããã«æé ãããæ©é¢åŒçšãšæ··ãåãããŠãããããè©äŸ¡ããæãè€éãªèŠçŽ ã§ããJennifer Ashton å士ã¯å®åšã®äººç©ã§ããã³ãã³ãã¢å€§åŠå»åŠéšã®å»åŠå士ã§èšç·Žãåããèªå®ç£å©Šäººç§å»ã§ãããABC News ã®äž»ä»»å»çéä¿¡å¡ãåããŸããã圌女ã®èæž The Self-Care Solution ããã³ãã®ä»ã¯å®åšã®åºçç©ã§ãã圌女㮠Good Morning America ããã³ The View ã§ã®åºæŒã¯ææžåãããŠããŸãããã®ç¯å²ãŸã§ãåºç€çãªèªå®è«æ±ã¯æ£ç¢ºã§ãããVSL ã¯æ¶ç©ºã®å»è ãçºæããŠããŸããã
æš©åšä¿¡å·ãåé¡ã«ãªãå Žæã¯ãæ©é¢ã®æšå¥šã®æé ãŸãã¯é床ã«èªåŒµãããããšã§ããVSL ã¯ãç±³åœã¡ãã£ã±ã¢ã»ã¡ãã£ã±ã€ãã»ãµãŒãã¹ã»ã³ã¿ãŒ (CMS) ã®ç®¡çè ãOz å士ããšããŠåŒçšããŠãããGLP-1/GIP ãã«ã¢ã³æŽ»æ§åã® 2025 幎ãã¬ã¹ã«ã³ãã¡ã¬ã³ã¹æšå¥šãå ±åãããŠããŸãããããŠãç¹ã« Jennifer Ashton å士ã®ãŒã©ãã³çºèŠãè³è³ããŠããŸããMehmet Oz å士㯠CMS 管çè ã®åœ¹å²ã«æåãããŸãããããã®åæã®æç¹ã§ã圌ã«å±æ§åãããåŒçšãšäžèŽããå ¬éææžåããããã¬ã¹ã«ã³ãã¡ã¬ã³ã¹ã¯ãããŸãããæ©æ§ãã¬ãŒãã³ã° (CMS 管çè ãç¹å®ã®ãµããªã¡ã³ãã®ã¡ã«ããºã ãæšå¥šãã) ã¯ãåãªãã«ãžã¥ã¢ã«ãªã¡ãã£ã¢åºæŒã§ã¯ãªããå®è³ªçãªèŠå¶è«æ±ãæ§æããŸãããã®åŒçšã¯ borrowed authority (åçšãããæš©åš) ãšããŠæ©èœããŸããå®åšããå ¬ç人ç©ããå ¬éææžåããã圢åŒã§ååšããªãå ¬åŒãªæšå¥šãæç€ºããæ©é¢åœ¹ã«é 眮ãããŸãã
ç§åŠã®åŒçšã¯åæ§ã«æ··åšããŠããŸããé»ã³ã·ã§ãŠ-ã¯ã«ã¯ãã³ãã€ãªã¢ãã€ã©ããªãã£ã®çºèŠã¯å®è³ªçã§ã (Shoba ããPlanta Medicaã1998)ãç·è¶æœåºç©ã®èèªé žåãžã®å¹æã¯ International Journal of Obesity ã®ãã¢ã¬ãã¥ãŒæžã¿ç ç©¶ã«ãã£ãŠãµããŒããããŠããŸãããã«ããªã³ã®ä»£è¬å¹æã¯ Metabolism ããã³ãã®ä»ã®éèªã«èšèŒãããŠããŸãããã ããGLP-1 ãš GIP ãæŽ»æ§åãã人ã ãé£äºçæ³ãšéåã®ã¿ããã74 åãäœéã倱ããšãã JAMA ç ç©¶ã¯ãã°ãªã·ã³ãžã® GLP-1 å¢å 182% ã屿§åãããã«ããªã³ã«ãããç®èåŒŸåæ§ããã³è¡æ¶²ã°ã«ã³ãŒã¹èª¿ç¯ã¯ãç¹å®ã®å ¬éè«æã«è¿œè·¡äžå¯èœã§ãã2018 幎ã®ã¹ã¿ã³ãã©ãŒãèšåºã±ãŒã¹ã¹ã¿ãã£ã®ã42 æ³ã®å¥³æ§ã®ã¡ã«ããºã 説æã®äžå¿ç©èª (èæœ°çãæã€) ã¯ãæ§æãããã€ã©ã¹ãç©èªãšããŠèªã¿ãŸããå¥éåŠè¡çãªã±ãŒã¹ã¬ããŒããéèªåã¯ãªããèè ããªããDOI ããªããå ¬éãããã±ãŒã¹ã¹ã¿ãã£ãšäžèŽãããšããæ£è èå¥åããããŸããããã®ã±ãŒã¹ã¹ã¿ãã£ã Mounjaro ã®éçºã®åºç€çãªåèãšããŠæ©èœãããšãã䞻匵ã¯ãæ€èšŒäžå¯èœã§ãããEli Lilly ã®ææžåããã tirzepatide ç ç©¶ã¿ã€ã ã©ã€ã³ (æ°å幎åã«å®æœãããã€ã³ã¯ã¬ãã³çç©åŠç ç©¶ã«è¿œè·¡ããã) ãäžããããå¯èœæ§ã¯ã»ãŒç¢ºå®ã«ãããŸããã
æå人ã®èšŒèšãã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ãRebel WilsonãKaty PerryãKathy BatesãOprah Winfreyãã¯ææžåãããããã¬ã³ãžã·ãããŸãã¯å人çãªæšå¥šãšããŠæç€ºãããŠããŸããã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã®äœéæžå°ã¯å®åšããŠãããå ¬çã«ææžåãããŠããŸãã圌女ã¯ã圌女ã¯ã圌女ã¯èçœè³ªãè±å¯ãªé£äºãšæ©ãããšãå§ããå»è ãšååããŠããã€ã³ã¿ãã¥ãŒã§è¿°ã¹ãŠããŸãã圌女ã¯å ¬çã« BurnSlim ãšåŒã°ãããŒã©ãã³ãµããªã¡ã³ããžã®å€èº«ã屿§åããŠããŸãããä»ã®æå人ã®å±æ§ã¯ãæ€èšŒã¡ã«ããºã ãªãã§æç€ºãããæªæ€èšŒã®è²©ä¿è«æ±ãšããŠæ±ãããã¹ãã§ãã
ãªãã¡ãŒãäŸ¡æ Œèšå®ããªã¹ã¯é転
BurnSlim ã®ãªãã¡ãŒæ§é ã¯ã極端ãªé«äŸ¡æ Œåç §ãã€ã³ãã«å¯ŸããŠåºå®ããããæ§ç¯ããããã«ãå±€ã®äŸ¡æ Œèšå®ãã¡ãã«ã§ããVSL ã¯ãã«ããŽãªãã³ãããŒã¯ãšã㊠$2,000/æã® Mounjaro ãã³ãå°å ¥ããæé ãããéèŠäŸ¡æ Œ $800 per bottle (ã顧客ããããæ¯æãããšãæäŸããã) ã確ç«ããŠãããåçãªåæžã·ãŒã±ã³ã¹ ($400 â $200 â $49) ãéããŠäŸ¡æ Œãæ©ããŠã6 ããã«ãããäŸ¡æ Œã«å°éããŸããããã¯ããã¹ãããã¯ç㪠price anchoring (äŸ¡æ Œã¢ã³ã«ãªã³ã°) ã·ãŒã±ã³ã¹ã§ãããããã§ã®ã¢ã³ã«ãŒã¯æ å ±ã§ã¯ãªãä¿®èŸçã«æ©èœããŸãã$2,000 ã®åç §ã¯ããããªãèŠå¶æèŠã§ãç«¶äºè£œåã§ã¯ãªãåŠæ¹å»è¬åã®ã³ã¹ãã§ããã$800 ã®éèŠäŸ¡æ Œã¯éžè©±çã§æªæ€èšŒã§ãããã ããå¿ççãªå¹æã¯å®åšããŸããæç€ºãããæåã®æ°åã¯ããã¹ãŠã®åŸç¶ã®æ°åãå°ããæããã¬ãã«ãšããŠèªç¥ã¢ã³ã«ãŒãšããŠæ©èœããŸãããã㯠Tversky ãš Kahneman ãåºç€çãªã¢ã³ã«ãªã³ã°ç ç©¶ã§ç¢ºç«ããçºèŠã§ãã
3 å±€ã®ãããæ§é (2 ããã« $79 åã3 ããã« $69 åã6 ããã« $49 å + 3 ç¡æ) ã¯ãµããªã¡ã³ããã¡ãã«èšèšã®æšæºã§ããã6 ããã«ãªãã·ã§ã³ãåäœåœããã®åºæºã«å€§å¹ ã«åªããæ°ä»ãããããšã§å¹³å泚æå€ãæå€§åããããæ§é åãããŠããªããåæã«ãäžå®å šãªæ²»çãµã€ã¯ã«ã«é¢ããèšèªãéããŠãå®å šæ§ãå§åãäœæããŠããŸããããŒãã¹ã¹ã¿ãã¯ã3 ã€ã®ããžã¿ã«ã¬ã€ããå»è ãšã®ãã©ã€ããŒã Zoom åŒã³åºããæåã® 10 人ã®è²·ãæã®ããã® $500 Zara ã®ããåžãããã³æåã® 25 人ã®è²·ãæããæœåºããã Mykonos ãªãŸãŒããžã®æ è¡ã¯ãèªè䟡å€ãèšããŸããæ®µéçãªåžå°æ§ãäœæããŠåºå¥ããŸããåæã®è²·ãæãé ãè²·ãæããã
60 æ¥éããã¹ãŠã®ããã«ãä¿æããã¬ã©ã³ãã£ã¯ããªãã¡ãŒã®æã匷åãªèŠçŽ ã§ããããã®æãæ£çŽãªèŠçŽ ã§ãããªã¹ã¯é転ã¡ã«ããºã ãšããŠãCialdini ã®è¿æžååãäºæž¬ããéãã«æ£ç¢ºã«æ©èœããŸãã販売è ã¯äœãé倧ãªãã® (ãªã¹ã¯ã®ãªã 2 ã¶æã®è©Šéšãè¿éã§ãããã«ãä¿æãã補å) ãäžããè²·ãæã¯è¿éãèŠæ±ããåã«è¯ãä¿¡ä»°ã§è©Šã察å¿ãã矩åãæããŸããã¬ã©ã³ãã£ã¯ãŸãã忥çã«åççã§ããé«ãè¿éçã¯çµæžçã«æç¶äžå¯èœã§ããã販売è ã補åãååã«æ©èœããŠè¿éãæå°åããããè¿éãéå§ããæ©æŠ (ã¡ãŒã«ãèŠã€ããããã¿ã³ãã¯ãªãã¯ãããåŸ ã€) ãçè«çãªã¬ã©ã³ãã£æå€§ãå®éã®è¿éã¬ãŒãã«å€§ããäœäžãããããšã瀺åããŠããŸãã
ããã¯èª°ã®ããã®ãã® (ãããŠèª°ã®ããã§ã¯ãªãã®ã)
BurnSlim ã®ã¿ãŒã²ããè²·ãæã¯ããã® VSL ãæ§ç¯ããéãã倱æããäœéæžå°ä»å ¥ã§å€§éã®çµéšãèç©ããã40 代ãã 60 代ã®å¥³æ§ã§ããè€æ°ã®é£äºçæ³ã詊è¡ããã³æŸæ£ãããŠããŸããçµæãçæããªãã£ããžã ã¡ã³ããŒã·ããããããããå¯äœçšãŸãã¯ã³ã¹ãã®ããã«çµäºããçåœã®æ³šå° GLP-1 å»è¬åå®éšã圌女ã¯åããŠã®ãã€ãšãã¿ãŒã§ã¯ãããŸããã圌女ã¯åžå ŽãæŽç·Žãããè²·ãæã§ãããã»ãšãã©ã®äœéæžå°è«æ±ãèããŠããŠãããããããžã®å¥å šãªã·ãã·ãºã ãéçºããŠããŸããããã¯ãŸãã« VSL ãçŽæ¥å©çè«æ±ã§ã¯ãªããã¿ãŒã³å²ã蟌ã¿ã§éãçç±ã§ãã圌女㯠Mounjaro ãš Ozempic ã«ãã¬ããžãèŠãå¯èœæ§ããããåºãçè§Šã§ãã¯ãŒ-1 ãäœã§ããããç¥ã£ãŠããŸãããããŠã圌女ã¯èªç¶çã®çŽæãæ¬åœã«é åçãšèŠã€ããŠããŸããæŠå¿µãšããŠã圌女ã¯ãŸã誰ãã§ããããã®çŸåšã®äœã®ææ çãªã³ã¹ãã¯ã瀟äŒçãªæ€éãã«ã¡ã©ã®åé¿ãé©åããªãã¯ãããã³ã°ã¯ãã¢ã¯ã·ã§ã³ãåæ©ä»ããã»ã©æ¥æ§ã§ããã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã®ãã©ãã£ãã¯ãååãªç¹ç°æ§ã§åœŒå¥³èªèº«ã®å éšç¬çœãåæ ããŠãããããå ·äœçãªåæ ã§ã¯ãªãèªèãšããŠçå°ããŸãã
ãã®è£œåã¯ãæççããã³ãã€ãªã¢ã¯ãã£ããªããããã£ãæã€äžè¬çãªä»£è¬ãµããŒããµããªã¡ã³ããæ±ããè²·ãæã«äœããã®å©çãæäŸããå ŽåããããŸãããã«ããªã³ãç·è¶ç±æ¥ EGCGãããã³ãŠã³ã³ãšé»ã³ã·ã§ãŠã®çµã¿åããã¯ããã¹ãŠé©åãªçšéã§ã®é©åãªãæ§ããã§ã¯ãããåæ³çãªã代è¬çããã³æçççãããã¡ã€ã«ãæã€æåã§ãããã©ãŒãã¥ã©ããããã®ååç©ã®èšåºçã«é¢é£ããæ¿åºŠãæäŸããå Žåãããã€ãã®è²·ãæã¯è¡ç³èª¿ç¯ãã³ã¬ã¹ãããŒã«ç®¡çãããã³ççäœäžã®ææãªãµããŒããçµéšããå ŽåããããŸããå©çã¯éæ¥çã«æéããããŠäœé管çããµããŒãã§ããŸãããã㯠VSL ã® 15 æ¥éã§ã® 27 ãã³ãã®äž»èŠãªçŽæãšã¯ææã«ç°ãªã£ãŠããŸãã
ææãªæ³šæã§æ¥è¿ããå¿ èŠãããè²·ãæã«ã¯ãVSL ã説æããèŠæš¡ãšé床ã§ã®çµæãæåŸ ããŠããè (15-60 ãã³ã 15-90 æ¥éãé£äºçæ³ãŸãã¯éåã®å€æŽãªã)ãæ¢åã®èèãç²ç¶è ºããŸãã¯è èã®ç¶æ ãæã€è (ãã«ããªã³ãšãŠã³ã³ã¯é«çšéã§ç¹å®ã®å»è¬åãšçžäºäœçšããèèã®çµè·¯ã«ã¹ãã¬ã¹ãäžããå¯èœæ§ããããŸã)ãè¡æ¶²åžèåå»è¬åãŸãã¯ç³å°¿ç å»è¬åãæåããŠããè (ãã«ããªã³ã¯ææžåãããã°ã«ã³ãŒã¹äœäžå¹æãæã€) å»è¬åãšè€ååããã³äœéæžå°ç®æšãå»åŠçã«ç·æ¥ã§ããè ããã®éå£ã«ã¯ããµããªã¡ã³ãã§ã¯ãªãèšåºç£ç£ãå¿ èŠã§ããVSL ã§èª¬æãããŠããæå人ã®èšŒèšããã³åçãªã±ãŒã¹ã¹ã¿ãã£ã¯ãåã ã®çµæã®äºæž¬å åãšããŠåããªãããã«ããŠãã ããã
GLP-1 ãã«ã¢ã³èšèªãããŒã±ãã£ã³ã°ã§äœ¿çšããä»ã®äœéæžå°ãµããªã¡ã³ãã調æ»ããŠããŸãã?Intel Services ã¯ãã®ã¹ããŒã¹ã§æ°åã® VSL ãåæããŸããã以äžã® FAQ ãšæçµçãªèŠæ¹ã«ã€ããŠåŒãç¶ããèªã¿ãã ããã
ãããã質å
Q: BurnSlim ã¯è©æ¬ºã§ãã?
A: BurnSlim ã¯åæ¥çã«å£²ãããŠãããµããªã¡ã³ãã§ãããååšããªã補åãšããæå³ã§ã®è©æ¬ºã§ã¯ãããŸãããããã瀺ããªã¹ãæå (ãŒã©ãã³ç±æ¥ã¢ããé
žãç·è¶æœåºç©ããã«ããªã³ãããã³ãŠã³ã³ãšé»ã³ã·ã§ãŠ) ã¯ãææžåãããçç©åŠç掻æ§ãæã€å®åšã®ååç©ã§ãããã ãããã®ããŒã±ãã£ã³ã°ã®ããã€ãã®äž»åŒµ (æåäººã®æšå¥šãç¹å®ã®äœéæžå°éåºŠãæ©é¢ã®åŒçšãå«ã) ã¯ç¬ç«ããŠæ€èšŒããããšãã§ãããå Žåã«ãã£ãŠã¯æé ãŸãã¯å®è³ªçã«èªåŒµãããŠããããã«èŠããŸããè²·ãæã¯ãèšåºçã«æ€èšŒããã Mounjaro ã®äº€æãšããŠã§ã¯ãªããæ§ãããªèµ·ããåŸã代è¬å©çãæã€ãµããªã¡ã³ããšããŠè©äŸ¡ããå¿
èŠããããŸãã
Q: BurnSlim ã¯æ¬åœã«äœéæžå°ã«æ©èœããŸãã?
A: BurnSlim ã®åã
ã®æåã¯ã代è¬ããã³æçç广ã«åæ³çã§ãããæ§ãããªãµããŒã蚌æ ãæã£ãŠããŸããç¹ã«ãã«ããªã³ãšç·è¶æœåºç©ã¯ãè¡æ¶²ã°ã«ã³ãŒã¹èª¿ç¯ãšæž©ããèèªé
žåããµããŒããããã¢ã¬ãã¥ãŒæžã¿ç ç©¶ãæã£ãŠããŸãããããã®å¹æã VSL ã§èª¬æãããŠããåçã§æ¥éãªäœéæžå° (27 ãã³ã 15 æ¥éã2 ã¶æåã§ 60 ãã³ããé£äºçæ³ãéåã®å€æŽãªã) ã«çµã¿åãããããã©ããã¯ãå
¬éäžã®ç§åŠæç®ã§å©çšå¯èœãªç¬ç«ããèšåºèšŒæ ã«ãã£ãŠãµããŒããããŠããŸããã
Q: BurnSlim ã®æåã¯äœã§ãã?
A: 4 ã€ã®ã³ã¢æåã¯ãçŽç²ãªãŒã©ãã³ (ã°ãªã·ã³ãšã¢ã©ãã³ã¢ããé
žãæäŸ)ãæ¥æ¬ã®ç·è¶æœåºç© (EGCG)ããã«ããªã³ãããã³ãŠã³ã³ (é»ã³ã·ã§ãŠãšçµã¿åããããã®) ã§ããVSL ã¯ãããã㯠Astellas Labs ãšã®ããŒãããŒã·ãããéããŠè£œè¬ã°ã¬ãŒãã®çŽåºŠã§ãœãŒã·ã³ã°ãããç±³åœã® FDA ç»é²ãGMP èªèšŒæœèšã§è£œé ãããŠããããšã䞻匵ããŠããŸããã«ãã»ã«ãããã®å
·äœçãªçšéã¯ã販ä¿è³æã«é瀺ãããŠããŸããã
Q: BurnSlim ãæåããã®ã¯å®å
šã§ãã?
A: äžè¬çã«å¥åº·ãªæäººã®å Žåããªã¹ããããæåã¯ãå
žåçãªãµããªã¡ã³ãçšéã§å®å
šã§ãããšèŠãªãããŸãããã ãããã«ããªã³ã¯ç³å°¿ç
å»è¬å (ã¡ããã«ãã³ãå«ã)ãè¡æ¶²åžèåå€ãç¹å®ã®æçç©è³ªãšçžäºäœçšããããšãã§ããŸãããŠã³ã³ã¯é«çšéã§ã¯è墿©èœã«åœ±é¿ãäžããå¯èœæ§ããããŸããåŠæ¹å»è¬åãåŠåš äžãæä¹³ããŸãã¯æ
¢æ§ç¶æ
ã管çããŠãã人ã¯ã䜿çšåã«å»è
ã«çžè«ãã¹ãã§ããVSL ã®ãå¯äœçšãªããã¯ãã¹ãŠã®ãŠãŒã¶ãŒã®ããã®äž»åŒµã¯é倧è©äŸ¡ã§ããåã
ã®å¿çã¯ä»»æã®ãµããªã¡ã³ãã«ç°ãªããŸãã
Q: BurnSlim ã®å¯äœçšã¯äœã§ãã?
A: VSL ã¯å¯äœçšããŒãã§ãããšäž»åŒµããŠããŸãããåã
ã®æåã®æ¢ç¥ã®å¯äœçšãããã¡ã€ã«ã¯ä»¥äžãå«ã¿ãŸãããã«ããªã³ãèè
žäžèª¿ãäžç¢ããããããç¹ã«é«çšéã§ãç·è¶æœåºç©é«çšéã§ã¯ãåãæ°ãèèã¹ãã¬ã¹ (ãŸããªå Žå)ãã«ãã§ã€ã³é¢é£å¹æããŠã³ã³é«çšéã§ã¯ãèžçŒããæ¶åäžå¿«æããããã¯ã©ããæšæºçãªãµããªã¡ã³ãã³ã³ããã¹ãã§å³ããã¯ãããŸããããäžæ¬ãå¯äœçšãªããè«æ±ã¯èª€è§£ãæããã®ã§ãã
Q: ã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã¯æ¬åœã« BurnSlim ã䜿çšããŸããã?
A: ã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã®äœéæžå°ã¯ãææžåããããããªãã¯ãã¡ã¯ãã§ãããã ããã¡ãã£ã¢ã€ã³ã¿ãã¥ãŒã§ã¯ã圌女ã¯å»è
ãšååããŠãããšè¿°ã¹ãŠãããã¿ã³ãã¯è³ªã«çŠç¹ãåœãŠãé£äºçæ³ãšæ©ãå¢å ãæšå¥šããŸããããŒã©ãã³ãµããªã¡ã³ãã§ã¯ãªããåœŒå¥³ãæšå¥šã䜿çšããŸã㯠BurnSlim ãšåŒã°ãã補åã®å®£äŒã«å ±é
¬ãåŸãããšã®å
¬éå¯èœãªç¢ºèªã¯ãããŸãããæå人ã®å®åšããå€èº«ããææžåãããèªå¯ãªãã§æé»ã®è£œåæšå¥šãšããŠäœ¿çšããããšã¯ãçŽæ¥å¿çãµããªã¡ã³ãããŒã±ãã£ã³ã°ã§äžè¬çã§æ³çã«ãªã¹ã¯æŽ»åã§ãã
Q: BurnSlim ã Mounjaro ãŸã㯠Ozempic ãšæ¯èŒãããšã©ãã§ãã?
A: Mounjaro (tirzepatide) ãš Ozempic (semaglutide) ã¯ãGIP ãš GLP-1 å容äœã«é«ãã¢ãã£ããã£ãšé·ãåæžæã§çŽæ¥çµåããåŠæ¹å»è¬åã§ãããèšåºè©Šéšã§ææžåãããå€§èŠæš¡ãªäœéæžå°ããããããŸããBurnSlim ã¯ãå
å æ§ã€ã³ã¯ã¬ãã³åæ³ãæ§ããã«åºæ¿ããå¯èœæ§ã®ããé£äºååç©ãå«ãŸããŠããŸãããããã¯ã«ããŽãªçã«ç°ãªãã¡ã«ããºã ã§ãããã«ããŽãªçã«ç°ãªã广ãµã€ãºã§ããBurnSlim ããå¯äœçšãªããã§ Mounjaro ãè€è£œããããšã䞻匵ããããšã§ãå»è¬åã°ã¬ãŒãã®å容äœäœåè¬ãšé£äºãµããªã¡ã³ãããç§åŠçã«æ¯æå¯èœãªæ¹æ³ã§æ··ãåãããŸãã
Q: äœéæžå°ã®ããã®ãŒã©ãã³ããªãã¯ã¯äœã§ãã?
A: BurnSlim ã® VSL ã§èª¬æãããŠããããŒã©ãã³ããªãã¯ãã¯ããŒã©ãã³ã®æºåãç·è¶æœåºç©ããã«ããªã³ãããã³ãŠã³ã³ (é»ã³ã·ã§ãŠæœåºç©) ãšçµã¿åãããŠæ¶è²»ããGLP-1 ãš GIP ãã«ã¢ã³åæ³ãèªç¶ã«åºæ¿ããããã«çè«åãããŠããŸããåºæ¬çãªã¢ã€ãã¢ãé£äºã¿ã³ãã¯è³ªãšç¹å®ã®ã¢ããé
žãã€ã³ã¯ã¬ãã³æŸåºãåºæ¿ã§ãããšããããšã¯ãæ é€ç§åŠã®ããã€ãã®æ ¹æ ãæã£ãŠããŸãããVSL ã®ãã®åçŽãªæºåã«å±ããŠãããã®åçãªäœéæžå°ã®çµæã¯ããã¢ã¬ãã¥ãŒæžã¿æç®ã§è€è£œãããŠããŸããã
æçµçãªèŠæ¹
BurnSlim ã®ãããªã»ãŒã«ã¹ã¬ã¿ãŒã¯ãåžå Žã®å®éã®ç·åŒµã«åºã¥ããŠãããããçŸä»£ã®çŽæ¥å¿çã¢ãŒããã¯ãã£ã®ãã¹ã¿ãŒã¯ã©ã¹ã§ããäœçŸäžäººãã®äººã ã GLP-1 å»è¬åãçæããçµæããã³ã¹ããæ³šå°ããŸãã¯ææžåããããªã¹ã¯ãªãã§å¿ èŠãšããŠããããã®æ¬²æãæºããããã«çŸåšåæ³çã§å®äŸ¡ãªãªãã·ã§ã³ã¯ååšããŸãããVSL ã¯ãã®ã®ã£ãããæ£ç¢ºã«èå¥ããç§åŠçãªåæ³æ§ã®ååãªãªã¹ããæã€è£œåã§ãæå人ã®èªèãå»åŠçæš©åšãæ©é¢ã®é°è¬ãããã³ææ çãªã«ã¿ã«ã·ã¹ã質ã®ç¡ãé åã«çµã¿åããããã©ãã£ãæ§é ã§æºãããŸããçµæã¯ãåºåã§ã¯ãªãããã¥ã¡ã³ã¿ãªãŒã®ããã«æ©èœãããããã§ãããã¿ãŒã²ããè²·ãæã¯éåžžããã·ããã€æ¹å€çã«èŠãæ§ãžã£ã³ã«ããããŠããã¯ãŸãã« VSL ã補é ããããã«èšèšãããèªç¥å§¿å¢ã§ãã
ãã¬ãŒã³ããŒã·ã§ã³ã®æã匷åãªèŠçŽ ã¯ãææ çãªãã©ãã£ã (ã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã®åŒ§ã¯æ¬åœã«åœ±é¿ãåããŠããŸã)ãç§åŠèªåœ (GLP-1ãGIPãã°ãªã·ã³ãã¢ã©ãã³ããããã®åšãã«æ§ç¯ãããè«æ±ãããã§ã¯ãªããšãã®ãããªçšèªã§ã)ãããã³ãªã¹ã¯é転 (60 æ¥éã®ä¿èšŒ) ã¯æ¶è²»è ä¿è·ãšããŠçå£ã«åãåãããã¹ãæå³ã®ããè²æ©) ã§ããæã匱ãèŠçŽ ã¯ãæå人ã®å±æ§ã®è«æ±ãç¹ã« Katy PerryãKathy BatesãOprah Winfrey ã®æªç¢ºèªããã䜿çšã¯ãæé»ã®æšå¥šè ãšããŠãæé ãŸãã¯èªåŒµãããæ©é¢åŒçš (Dr. Oz CMS ãã¬ã¹ã«ã³ãã¡ã¬ã³ã¹ãåç §åŒçšå¯èœãªåŒçšããªã 2018 幎ã®ã¹ã¿ã³ãã©ãŒãã±ãŒã¹ã¹ã¿ãã£)ãããã³äœéæžå°éåºŠè«æ±ããã㯠listed ã®æåã劥åœã«çæã§ãããã®ãããæ¡éãã«å€§ãã代è¬å¹æãå¿ èŠãšããçµæã説æããŠããŸãã
ãªãµãŒãæåã®è²·ãæã«ãšã£ãŠãæ£çŽãªãã¬ãŒãã³ã°ã¯æ¬¡ã®éãã§ããBurnSlim ã«ã¯ãè¡æ¶²ã°ã«ã³ãŒã¹èª¿ç¯ãççäœäžãããã³èèªé žåãžã®æ§ãããªå¹æã®ããã®åæ³çãªãã¢ã¬ãã¥ãŒæžã¿ãããã³ã°ãæã€ä»£è¬ãµããŒãæåã®çµã¿åãããå«ãŸããŠããŸãããããæ±ããã¡ãªããã§ããäžè¬çãªä»£è¬ãµããŒã (劥åœãªå®å šãããã¡ã€ã«ã§)ã補å㯠6 ããã«ãããã®åŠ¥åœãªäŸ¡æ Œã§é ä¿¡ãããå ŽåããããŸããããªãã 2 ã¶æåã§ 60 ãã³ãã倱ãããšãæåŸ ããŠããå Žåã¯ãé£äºçæ³ãéåã®ç¿æ £ã倿Žããã«ãæå人ã®å€èº«ãåããã©ãŒãã¥ã©ã«å±ããŠããããããã®æåŸ ã¯å©çšå¯èœãªç§åŠã«æ ¹ãããŠãããã倱æã«ã€ãªããå¯èœæ§ããããŸãã
ãã® VSL ãåžå Žã»ã°ã¡ã³ãã«ã€ããŠæããåºãæèšã¯ãGLP-1 å»è¬åçŸè±¡ãããµããªã¡ã³ã販売è ãä»åŸæ°å¹Žéãåããããšã«ãªãæ°žç¶çãªååŸã®æåçåç §ãã€ã³ããäœéæžå°ã®ããã«äœæãããšããããšã§ããé«ãå»è¬åã³ã¹ããææžåãããå¯äœçšãããã³åçãªèŠèŠç倿ã®çµã¿åããã¯ãèªç¶ã§æé ãªäŸ¡æ Œã®ä»£æ¿åãšããŠããèªäœã劥åœã«äœçœ®ä»ããããšãã§ããä»»äœã®è£œåã®ããã®ã»ãŒæµæã§ããªãåæ¥çæ©äŒãçæããŠããŸããBurnSlim ã¯ãã®ããžã·ã§ãã³ã°ãå®å šã«å ããæåã®æãæŽç·Žããã補åã®äžã«ãããŸããããã¯æåŸã§ã¯ãããŸããã
ãã®åæã¯ Intel Services ã®äžéšã§ãããVSL ããã³åºåã³ããŒåæã®ç¶ç¶çãªã©ã€ãã©ãªã§ãã代è¬ãµããªã¡ã³ã空éã®åæ§ã®è£œåã調æ»ããŠããå Žåã¯ãåŒãç¶ããèªã¿ãã ããã
å 責äºé : ãã®èšäºã¯ç ç©¶ããã³æè²ç®çã®ã¿ã§ããå»ççãæ³çããŸãã¯è²¡åçãªã¢ããã€ã¹ã§ã¯ãªãã補åãŸãã¯ãã®è£œé æ¥è ã«é¢é£ããŠããŸãããå¥åº·ãŸãã¯è²¡åã®æ±ºå®ãäžãåã«åžžã«é©æ Œã®å°éå®¶ã«çžè«ããŠãã ããã
Comments(0)
No comments yet. Members, start the conversation below.
Related reads
- DISreviews
BurnFlow ã¬ãã¥ãŒãš VSL åæ
BurnFlow ãããªã»ãŒã«ã¹ã¬ã¿ãŒã®ãªãŒããã³ã° 30 ç§ã¯ã補åããå§ãŸããŸãããã»ã¬ããªãã£ã®åçœããå§ãŸããŸãããã¬ãŒã³ã¿ãŒã¯ã女åªã¬ãã«ã»ãŠã£ã«ãœã³ãšã®ãã¬ã¹ã€ã³ã¿ãã¥ãŒãšããŠãã¬ãŒãã³ã°ããããã®ããé³èªããŸãããã®äžã§ãåœŒå¥³ã¯æ¯æãŒã©ãã³ãã¥ãŒããé£ã¹ãããšã§ 2 ã¶æã§ 77 ãã³ãäœéãèœãšããããšã«ã€ããŠèª¬æããŠããŸããããžã ãªããæ°çããã¿ããã€ãšãããªããããŒãããã¢ã€ã¹ã¯ãªãŒã ããã¶ã諊ããã«ããšã®ããšã§ãâŠ
Read - DISreviews
GumAktivã¬ãã¥ãŒãšåºååæïŒãªãµãŒããã¡ãŒã¹ãã®èå¯
GumAktivãããªã»ãŒã«ã¹ã¬ã¿ãŒïŒVSLïŒã®åé æ°ç§éã¯ãã¹ã¯ããŒã«äžã®ãã¥ãŒã¢ãŒãéã¥ãã«ããããã«èšèšããã質åãå±éããŸãïŒããããã®éããã¯ããªã¢ã¯ãæ¯ç§ã€ã³ãã©ã³ããããéããããè¿ éã«ããªãã®æ¯ã修埩ã§ããã§ããããïŒããšãããã¬ãŒãº...
Read - DISreviews
Arthrocel (RejuvaJoint) VSL ããã³åºååæ
ãããªã¯èšç®ãããç·è¿«æã®ãã声ã§å§ãŸããŸãïŒãçŸä»£å»åŠãé¢ç¯çãšé¢ç¯çã«ã€ããŠç¥ã£ãŠãããšæã£ãŠããããšã¯ãä»ãæ·±å»ãªçåã«ãããããŠããŸããã30ç§ä»¥å ã«ãã¹ã¿ã³ãã©ãŒã倧åŠãåŒãåãã«åºããããªãºå士ãèšåãããããŒãµã»ã¹ãã¥ã¯ãŒããåæå¯žåã®æ£è ãšããŠç޹ä»ãããèŠèŽè ã¯ãæ¢åã®ããããæ²»çæ³ãã9å广çãªããã·ã³ãã«ãªæäœãã¬ã·ãããçŽæãããŠããŸãâŠ
Read